Aladdin Sane
5 días hace
Latest post from Venkat on the bright future of Vyome. I'm not sure how LICH will unfold, but if Vyome becomes a major biotech player, I'm sure LICH will be part of the success story in some way.
https://www.linkedin.com/feed/update/urn:li:activity:7309165306491375617/
The immuno-inflammatory disease space is witnessing rapid growth, driven by major FDA approvals and a surge in novel drug development. AbbVie’s SKYRIZI® (risankizumab-rzaa) was recently approved for ulcerative colitis, expanding its indications across multiple immune-mediated diseases, while Eli Lilly’s Omvoh secured expanded FDA approval for Crohn’s disease, reinforcing the potential of targeted drugs. With next-gen biologics, small-molecule therapies, and precision-based treatments reshaping the industry, the market is poised for significant expansion. The global anti-inflammatory drugs market is expected to grow from $130.7B in 2024 to $272.35B by 2033 (CAGR: 8.5%), while the immunology market is projected to reach $254.23B by 2032. Additionally, the autoimmune disease therapeutics market is set to hit $200B by 2031, driven by increasing disease prevalence and innovation.
With its cutting-edge pipeline of therapies targeting high-unmet-need immuno-inflammatory diseases, Vyome Therapeutics is positioned in the right space at the right time. By leveraging the US-India innovation corridor, Vyome is driving progress in a cost-efficient manner while maintaining world-class R&D and execution. With its proprietary platforms and clinical-stage programs, Vyome Therapeutics, Inc. is focused on delivering first- and best-in-class solutions that can transform patient care. As the industry accelerates toward precision-based treatments, the opportunities are vast, and Vyome is fully aligned with this momentum. Exciting times ahead for biotech and immuno-inflammatory innovation!
thundersteel
4 semanas hace
Eagle, yes, gg was very savvy to purchase at .0025. I’ve been nibbling
Myself the past several weeks. It has cut my price in half. Looks more advantageous
to make some money at my new level.
Though, I do not understand your first point. Are you saying that due to a new ruling
on Pennie’s, you can no longer buy them due to your broker? I have E*Trade.never
Had an issue….though I know many institutions/brokers won’t let you buy them.
I agree, though, with this float…anything under .01 is a fantastic bet…..but, we
shall see…
If we get more vol soon and break .01…than I’ll start to believe a bit…till than,
I’ll buy 10-25,ooo weekly….
TS
thundersteel
1 mes hace
I fully understand your frustration in every regard. Imho, with this float I can’t understand
For the life of me, why in the long wait we never saw a pump. I’ve seem many Pennie’s, for
no reason, rocket up on groups coming in and causing a pump in price ; by squeezing the
algorithm. Especially, when you consider how many shares are held outside the retail
allotment.
The truly interesting aspect now is going to see if you get .0093 or if this will cause a stale
mate in bid vs ask pricing and volume. As for me, I’ll be camped out in the .005 range. But,
If someone takes your remaining shares..could see an attempt at .01 or higher.
Should be an interesting watch to see how the short term trading plays out…good luck.
We all have our tolerance , time, and waiting limits…..good luck..
thundersteel
1 mes hace
So, who is the mystery person…I’ve been nibbling…while someone else
Has been gobbling…..hmmmmm. Makes me think is a short covering at .0069, hence
all the shares. A prearranged buy or sell for an insider. Can’t see it being a sell, if the
Shell is going to be sold..There has been over 1.4 million under the ask…so, who is
buying these shares and why? I’ve nibbled 25,000 several times…but someone perhaps
Here has been banging that ask hard…..who is it?